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1302HLA DR15 Antigen Status Does Not Impact
Graft-versus-Host Disease or Survival in HLA-Matched
Sibling Transplantation for Hematologic Malignancies
Minoo Battiwalla,1 Kristin Ellis,2 Peigang Li,2 Steven Z. Pavletic,3 Gorgun Akpek,4
Peiman Hematti,5 Thomas R. Klumpp,6 Richard T. Maziarz,7 Bipin N. Savani,8
Mahmoud D. Aljurf,9 Mitchell S. Cairo,10 William R. Drobyski,11 Biju George,12
Theresa Hahn,13 Nandita Khera,14 Mark R. Litzow,15 Alison W. Loren,16 Wael Saber,2
Mukta Arora,17 Alvaro Urbano-Ispizua,18 Corey Cutler,19
Mary E. D. Flowers,14 Stephen R. Spellman20The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure
states. DR15 has also been associated with favorable outcomes (reduced acute graft-versus-host disease
[aGVHD] and relapse) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on
transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem
cell transplant from HLA-matched sibling donors for the treatment of acute leukemia, chronic myeloid
leukemia, or myelodysplastic syndrome (MDS) between 1990 and 2007. All patients received conventional
myeloablative conditioning, T-replete grafts, and cyclosporine plus methotrexate-based GVHD prophylaxis.
DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%)
as negative for DRB1*15:01 or *15:02 (DR15). There were no significant differences in baseline character-
istics between the HLA DR15 positive and negative groups. In univariate analysis, HLA-DR15 status had
no impact on neutrophil engraftment, aGVHD, chronic GVHD (cGVHD), treatment-related mortality, re-
lapse, disease-free survival, or overall survival (OS). In multivariate analysis, DR15 status showed no signif-
icant difference in aGVHD, cGVHD, OS, or relapse. In conclusion, DR15 status had no impact on major
HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort
of patients with leukemia and MDS.
Biol Blood Marrow Transplant 18: 1302-1308 (2012) Published by Elsevier Inc on behalf of American Society for Blood and
Marrow Transplantation
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DR15 (common alleles *15:01, *15:02) is a rela-
tively commonHLA class IIDRB1 antigenwith a pop-
ulation frequency between 20% and 30% in various
racial groups [1,2]. DR15 status has emerged as an
important marker in immune-mediated marrow fail-
ure states such as severe aplastic anemia (SAA), myelo-
dysplastic syndrome (MDS), and paroxysmal
nocturnal hemoglobinuria. Serological HLA DR2,
subsequently resolved as HLA DR15 (or HLA
DR16, respectively) by molecular HLA typing, has
been found at a higher frequency in patients with
SAA from many racial groups [3-12]. Of the 30
different DR15 alleles, only *15:01 and *15:02 have
been shown to have significantly higher frequencies
in patients with SAA compared with the normal
population. Diazepam-binding inhibitor-related
protein-1, a candidate auto-antigen in SAA is pre-
sented by DR15 [13]. The presence of the DR15 anti-
gen is not only overrepresented in marrow failure
states, but also reported to predict response to immu-
nosuppressive therapy, although this remains contro-
versial [14-16].
Putative mechanistic explanations for the associa-
tion of HLA DR15 with auto immune marrow failure
states include the possibility that DR15may present an
immunodominant myeloid epitope. Both epitope pre-
sentation (mediating graft-versus-malignancy effects)
and susceptibility to immunosuppressive therapy (re-
flecting the responsiveness of graft-versus-host
disease [GVHD] to treatment) are themes that are
commonly explored in allogeneic stem cell transplan-
tation. The role of DR15 status in allogeneic stem
cell transplantation was first examined in a cohort of
167 related and unrelated HLA-matched allogeneic
transplants for myeloid malignancies [17,18]. HLA
DR15 was identified either by molecular or
serological methods. Patients with HLA DR15
experienced a significantly lower incidence of acute
GVHD (aGVHD) grades II to IV: 23% versus 42%
(P 5 .041) without any significant difference in
chronic GVHD (cGVHD) incidence, progression-
free survival, or overall survival (OS). In contrast, in
a study of 192 HLA-identical sibling transplantations
for acute or chronic leukemia or non-Hodgkin lym-
phoma, Stern et al. [19] showed that the presence of
the DR15 antigen resulted in a higher estimated 5-
year OS (76% versus 55%; P5 .04). Improved survival
for DR15 patients was due to a significant decrease in
death from relapse (5% for DR15(1) versus 24% for
DR15(2); P 5 .02), whereas no difference was seen
for rates of transplantation-related mortality (19%
and 21%, respectively; P 5 .76). Davidson et al. [20]
also showed reduced relapse rates and improved OS
(74% versus 54%; P 5 .01) in 286 adult recipients ofHLA-matched sibling transplantations. The relevance
of DR15 has been disputed by Newell et al. [21] who
have shown in a study of 7950 patients with MDS and
chronicmyelogenous leukemia (CML) thatTNFpoly-
morphisms (in linkage disequilibrium with HLA-DR
B1) affect transplant outcome in a disease-dependent
manner.
Confirming that DR15 has a role in immunolog-
ical outcomes would help further efforts to character-
ize immunodominant epitopes responsible for graft-
versus-lymphoma effects, allow individualization of
GVHD prophylaxis, and encourage studies to pro-
vide a mechanistic explanation for the unique immu-
nological outcomes related to this specific DR
antigen. Therefore, we conducted a retrospective
analysis using a large database from the Center for
International Blood and Marrow Transplant Re-
search (CIBMTR) to further evaluate the prognostic
implications of DR15 on major transplantation out-
comes. The current study was confined to HLA-
identical sibling transplantations to eliminate any
HLA-disparity as a driving force for observed
differences.METHODS
Data Source
Patient, disease, transplantation characteristics,
and outcome data reported to the CIBMTR were
used for the current study.TheCIBMTR is a voluntary
working group of over 400 transplantation centers
worldwide that contribute data on consecutive hema-
topoietic transplantations to a Statistical Center at
the Medical College of Wisconsin. Computerized er-
ror checks, physician review of data, and on-site audits
ensure data quality. All patients are followed longitudi-
nally, annually. This study was approved by the Insti-
tutional Review Board of the Medical College of
Wisconsin.Inclusion Criteria
Patients with acutemyeloid leukemia (AML), acute
lymphocytic leukemia (ALL), MDS, or CML who un-
derwent first myeloablative marrow or mobilized pe-
ripheral blood stem cell HLA-matched sibling donor
transplantation between 1990 and 2007 were included
in this analysis. In order to stringently evaluate the im-
pact on GVHD, the study population excluded in vivo
and ex vivo T cell depletion and those receiving pro-
phylaxis other than cyclosporine plus methotrexate
1/2 other. Selection was confined to HLA-identical
sibling donor transplantations usingmarrowor periph-
eral blood stem cells. To differentiate DR15 from
DR16, the serological splits of DR2, we limited
1304 Biol Blood Marrow Transplant 18:1302-1314, 2012M. Battiwalla et al.eligibility to patients for whom high-resolution (allele-
level) typing at the HLA–DRB1 locus was available.
Outcomes
The study evaluated the impact of the DR15 on
outcome with grades B-D and C-D aGVHD,
cGVHD, relapse, and OS as the primary endpoints
and neutrophil engraftment, treatment-related mor-
tality (TRM), and disease-free survival (DFS) as sec-
ondary endpoints. The influence of age, disease
(‘‘lymphoid’’ versus ‘‘myeloid’’), and graft source (mar-
row versus peripheral blood), which were outcomes
specific to the two common alleles (*1501 and
*1502), were also planned with secondary analyses to
be performed in the event of a positive finding in a pri-
mary outcome measure. The incidence of grades B-D
aGVHD was determined during the first 100 days af-
ter transplantation and was defined according to the
CIBMTR scale [22]. Chronic GVHD was defined ac-
cording to the Seattle criteria [23]. Relapse of malig-
nancy was defined as reported to the CIBMTR by
the transplantation center. OS considered death
from any cause as the event, and surviving patients
were censored at the date of last contact. Neutrophil
engraftment was defined as achieving an absolute neu-
trophil count greater than 500  106/L for three con-
secutive measurements. DFS failure was defined as
relapse or death from any cause with patients who
were alive and in complete remission censored at the
time of last follow-up. TRM was defined as death dur-
ing a continuous complete remission. Events were
summarized by the cumulative incidence estimate
with relapse as a competing risk.
Statistical Analysis
Patient-related, disease-related, and transplantation-
related factors were compared between the DR15(1)
and the DR15(2) groups using the chi-square test for
categorical variables and the Mann-Whitney U test for
continuous variables. The probabilities of hematopoietic
recovery and acute and chronic GVHD were estimated
using the cumulative incidence function, treating death
without the event as a competing risk. The probability
of survival was calculated using the Kaplan-Meier
estimator [24]. Risk factors for transplantation outcomes
were identified through a stepwise forward/backward
model selection procedure. Cox proportional hazard
regression models were applied to evaluate the primary
outcomes of OS, relapse, grades B-D andC-D aGVHD,
and cGVHD. All variables were tested for the propor-
tional hazards assumption. A backward and forward
stepwise model building approach was used to stratify
variables that violated the proportional hazards
assumption. The variable for molecularly defined
DR15 status (DR15[1] versus DR15[2]) was forcedinto the models in all steps of model building and the
final model regardless of its statistical significance. Vari-
ables that attained a P value #.05 were held in the final
multivariate models.
Other variables tested were: age (in decades),
donor–recipient cytomegalovirus (CMV) serostatus
(donor and recipient seronegative versus donor and/
or recipient seropositive), disease type (lymphoid ver-
sus myeloid), graft source (marrow versus peripheral
blood), disease status (early, intermediate, advanced,
other/unknown), performance score (#80% versus
$90%), race, and year of transplantation (1990-1993
versus 1994-1997 versus 1998-2001 versus 2002-
2005 versus 2006-2007). All variables were tested to
ensure they met the proportional hazard assumption.
Variables that did not meet this assumption were ad-
justed by stratification. All P values are 2-sided. Anal-
yses were performed using SAS version 9.1 (SAS
Institute Inc., Cary, NC).RESULTS
Patients and Characteristics
A total of 2891 recipients of HLA-matched sib-
ling hematopoietic cell transplantations between
1990 and 2007 were included in this study. Among
the study cohort, 732 patients (25.3%) were positive
for DR15 (DR15[1]) and 2159 (74.7%) patients
were negative for DR15 (DR15[2]). The character-
istics of all patients are shown in Table 1. Sixty-
seven patients were homozygous for DR15 and
were combined with the DR15 heterozygous group.
There were no significant differences in baseline
transplantation characteristics by DR15 status apart
from race and an excess of AML compared to
CML in patients with DR15. Hardy-Weinberg equi-
librium was evaluated for the distribution of the
DR15 antigen within the study population. The
observed distribution of DR15 homozygosity did
not deviate from Hardy-Weinberg equilibrium
(P 5 .32 in the white cohort), and frequencies
were comparable to those observed in the major
U.S. race/ethnicity populations by the National
Marrow Donor Program [25].Graft-versus-Host Disease
Univariate analysis showed that the probability of
grades B-D aGVHD did not differ between the
DR15 groups, with 39% and 38% (P 5 .414) at 100
days after transplantation for the DR15 positive and
negative groups, respectively (Figure 1). Grade C-D
aGVHD rates did not differ as well (P 5 .270 at 100
days). The rates of cGVHD at 1 and 3 years were sim-
ilar between the DR15 groups, but there was
Table 1. Characteristics of Patients Receiving Myeloablative
Transplant fromHLA-Identical Sibling for AML, CML, ALL, or
MDS, Reported to CIBMTR between 1990 and 2007
Characteristics of Patients DR15(+) DR15(2) P value
Patient-related
Number of patients 732 2159
Number of centers 156 207
Age at transplantation, median
(range), years
34 (1-66) 34 (1-71) .298
Age in decades .365
0-9 42 (6) 162 (8)
10-19 121 (17) 347 (16)
20-29 143 (20) 389 (18)
30-39 153 (21) 503 (23)
40-49 180 (25) 490 (23)
50-59 93 (13) 268 (12)
Gender .676
Male 418 (57) 1217 (56)
Female 314 (43) 940 (44)
Missing 0 2 (<1)
Race .006
White 594 (81) 1729 (80)
African American 29 (4) 45 (2)
Asian/Pacific Islander 53 (7) 132 (6)
Hispanic 34 (5) 161 (7)
Native American 2 (<1) 13 (<1)
Other 13 (2) 59 (3)
Unknown/missing 7 (<1) 20 (<1)
Karnofsky score .989
<90% 156 (21) 458 (21)
$90% 567 (77) 1673 (77)
Missing 9 (1) 28 (1)
Disease-related
Disease .001
AML 291 (40) 747 (35)
ALL 184 (25) 516 (24)
CML 198 (27) 750 (35)
MDS 59 (8) 146 (7)
Disease status at transplantation* .879
Early 453 (62) 1361 (63)
Intermediate 140 (19) 415 (19)
Advanced 132 (18) 366 (17)
Other/unknown 7 (<1) 17 (<1)
Transplantation-related
Common conditioning drug
combinations
.974
TBI+Cy+/2other 249 (34) 742 (34)
TBI+/2other (no Cy) 54 (7) 162 (8)
Cy+Bu+/2other (no TBI) 429 (59) 1255 (58)
DR sex match .916
M-M 228 (31) 679 (31)
M-F 162 (22) 466 (22)
F-M 191 (26) 537 (25)
F-F 149 (20) 471 (22)
Missing 2 (<1) 6 (<1)
D-R CMV match .318
Neg-Neg 361 (49) 1084 (50)
Neg-Pos 66 (9) 242 (11)
Pos-Pos 103 (14) 278 (13)
Pos-Neg 183 (25) 490 (23)
Missing 19 (3) 65 (3)
Graft type .167
Bone marrow 399 (55) 1240 (57)
Peripheral blood 333 (45) 919 (43)
Year of transplantation .966
1990-1993 7 (<1) 25 (1)
1994-1997 245 (33) 705 (33)
1998-2001 243 (33) 722 (33)
2002-2005 199 (27) 584 (27)
2006-2007 38 (5) 123 (6)
GVHD prophylaxis .966
CSA+MTX+/2other 732 2159
Median follow-up of survivors, mo 74 (1-226) 74 (1-220)
Biol Blood Marrow Transplant 18:1302-1314, 2012 1305HLA DR15 in HSCT for Malignanciesa suggestion of a difference at 5 years, with 46% and
41% (P 5 .044) for the DR15 positive and negative
groups, respectively (Figure 1).
Multivariate analysis found significant associations
between grade B-D aGVHD and increasing patient
age (P\ .0001), CMV positive recipient (P 5 .0109),
peripheral blood stem cell (PBSC) grafts (P\ .0001),
and Karnofsky performance score \90 (P 5 .0078).
After adjusting for the significant covariates, no
association was found based on the presence of
DR15 (P 5 .782; Table 2). Statistically significant as-
sociations were found between grade C-D aGVHD
and increasing patient age (P 5 .0008), PBSC grafts
(P 5 .0003), Karnofsky performance score \90
(P 5 .0072), and transplantations before 1995
(P 5 .0038). After adjustment for the significant cova-
riates, no association was found based on the presence
or absence of DR15 (P 5 .548; Table 2). Chronic
GVHD was significantly associated with increasing
patient age (P\ .0001), female donors (P\ .0001),
and transplantations before 1995 (P5 .0136). After ad-
justing for the significant covariates, no association
was found based on DR15 positivity (P 5 .276;
Table 2). This suggests that the marginally significant
difference detected at 5 years in the univariate analysis
was due to uncontrolled confounding.Relapse
The probability of relapse was not different be-
tween the 2 groups, with 31% and 32% relapse at 5
years (P 5 .944) in the DR15 positive and negative
groups, respectively (Figure 1).
Multivariate analysis found significant associations
between relapse rates and CMV positive recipients
(P 5 .0392) and lymphoid disease (P 5 .0020). After
adjusting for the significant covariates, no association
was found between relapse and presence of DR15
(P 5 .612; Table 2).Overall Survival
Similar probability of OS at 52% at 5 years was ob-
served for both theDR15 positive and negative cohorts
(Figure 1).AML indicates acute myelogenous leukemia; CML, chronic myelogenous
leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic
syndrome; CIBMTR, Center for International Blood and Marrow Trans-
plant Research; TBI, total body irradiation; Cy, cyclophosphamide; Bu,
busulfan; CMV, cytomegalovirus; GVHD, graft-versus-host disease;
CSA, cyclosporine; MTX, methotrexate.
*Disease status is categorized as follows:
Early 5 AML/ALL (CR1), CML (CP1), MDS (RA/RARS/pre-HCT marrow
blasts <5%);
Intermediate 5 AML/ALL ($CR2), CML (AP or $CP2);
Advanced5 AML/ALL (REL/PIF), CML in BP, MDS (RAEB/RAEB-t/CMML or
marrow blasts $5%);
Other/unknown 5 everything else.
Figure 1. There was no statistically significant difference between the two groups in the cumulative incidences of aGVHD, cGVHD, relapse
and overall survival. CI, cumulative incidence; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; OS, overall
survival.
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between OS and increasing patient age (P\ .0001),
CMVpositive recipients (P5 .0136), lymphoid disease
(P \ .0001), intermediate or advanced disease
(P \ .0001), PBSC (P 5 .0014), lower Karnofsky
performance score (P \ .0001), non-white patients
(P 5 .0058), and transplantations before 1995
(P 5 .0145). After adjusting for all significant covari-
ates, no association was found between OS and the
presence of DR15 (P 5 .441; Table 2).
A bias assessment was performed for included ver-
sus excluded cases based on the availability of molecu-
lar typing. This found no significant difference in the
probability of OS at 1, 3, and 5 years posttransplanta-
tion, between the 2859 included and 3470 excluded
cases. Any potential selection bias based on the avail-
ability of DRB1 molecular typing did not influence
the outcomes of the study.Engraftment
The probability of neutrophil engraftment did not
differ between the groups, with 97% of patients en-grafting by day 100 (P 5 .568) in both the DR15 pos-
itive and negative groups. Multivariate analyses were
not performed on the secondary outcomes due to the
lack of difference in the univariate analysis.Treatment-Related Mortality
The probability of TRMdid not differ between the
groups, with 23% and 22% at 5 years (P5 .677) in the
DR15 positive and negative groups, respectively. Mul-
tivariate analyses were not performed for secondary
outcomes due to the lack of a difference in the univar-
iate analysis.Disease-Free Survival
The probability of DFS did not differ between the
groups, with 46% DFS at 5 years (P 5 .785) for both
the DR15 positive and negative groups. Multivariate
analyses were not performed on the secondary out-
comes due to the lack of difference in the univariate
analysis.
Table 2. Multivariate Analysis Results
Outcome
DR15(+)* DR15(2)
P valueRR (95% CI)
Acute GVHD B-D† 1.00 1.02 (0.89-1.16) .782
Acute GVHD C-D‡ 1.00 0.94 (0.78-1.14) .548
Chronic GVHD§ 1.00 0.93 (0.81-1.06) .276
Relapsejj 1.00 1.04 (0.89-1.21) .612
Overall survival¶ 1.00 1.05 (0.93-1.19) .441
RR indicates relative risk; CI, confidence interval; GVHD, graft-versus-
host disease.
*Reference group.
†Significant covariates: increasing patient age (P < .0001), cytomegalovi-
rus (CMV) positive recipient (P 5 .0109), peripheral blood stem cell
(PBSC) grafts (P < 0.0001), and Karnofsky performance score <90
(P 5 .0078).
‡Significant covariaties: increasing patient age (P 5 .0008), PBSC grafts
(P 5 .0003), Karnofsky performance score <90 (P 5 .0072), and trans-
plantations before 1995 (P 5 .0038).
§Significant covariates: increasing patient age (P < .0001), female donors
(P < .0001), and transplantations before 1995 (P 5 .0136).
jjSignificant covariates: CMV positive recipients (P 5 .0392) and lym-
phoid disease (P 5 .0020).
¶Significant covariates: increasing patient age (P < .0001), CMV positive
recipients (P5 .0136), lymphoid disease (P < .0001), intermediate or ad-
vanced disease (P < .0001), PBSC (P 5 .0014), lower Karnofsky perfor-
mance score (P < .0001), non-white patients (P 5 .0058), and
transplantations before 1995 (P 5 .0145).
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Previous studies have examined the role of DR15
in HLA-matched hematopoietic cell transplants with
conflicting results. The current study used a large ho-
mogeneous dataset from the CIBMTR with differ-
ences in study populations, which could explain the
discrepant observations. The studies by Battiwalla
et al. [17,18] found that DR15-reduced aGVHD
included unrelated donor transplantations but
without high-resolution typing for all patients, a set-
ting in which aGVHD could be more pronounced.
The study by Stern et al. [19], which showed that
DR15 presence was associated with reduced DFS,
was confined to HLA-identical siblings but had more
PBSC grafts, more advanced disease, inclusion of lym-
phomas, inclusion of reduced intensity conditioning,
and diverse GVHD prophylaxis. The study by David-
son et al. [20], which also found an association between
DFS and DR15, did not report multivariate analysis,
but the study population was apparently very similar
to the population studied by Stern.
Our study used careful selection criteria to avoid
HLA-disparity, excluded low-resolution DRB1 typ-
ing, and defined a homogenous cohort of patients
(myeloablative, T-lymphocyte replete transplanta-
tions with uniform cyclosporine plus methotrexate-
based GVHD prophylaxis). In this setting, DR15
status did not account for significant differences inclinical outcomes such as survival, relapse, or
GVHD. This was noted on univariate analysis and
confirmed on multivariate analysis. Confining the uni-
variate analysis to myeloid malignancies did not alter
these findings. Multivariate analysis was restricted to
the primary outcomes defined for the study: OS, re-
lapse, grades B-D and C-D aGVHD, and cGVHD,
due to lack of significance for any of the secondary out-
comes in the univariate analysis.
Our study was confined to HLA-identical sibling
transplantations, and the role, if any, of DR15 in unre-
lated or mismatched transplantations cannot be deter-
mined. Alternative explanations for immunobiologic
outcomes related to DR15 need to be considered.
DR15 is associated with the DRB1*1501-DRB5*0101-
DQB1*0602 haplotype. Linkage disequilibrium with
other non-HLA immunogenetic factors, such as
TNF-a, could also account for immunological out-
comes attributed to DR15 [21]. Although our findings
reduce the prospect for DR15-based therapeutic inter-
vention in the allogeneic transplantation setting, they
do not diminish the influence of this unique HLA class
II antigen in the nontransplantation setting for marrow
failure states.
In conclusion, in a large datasetwith a homogenous
population,HLADR15 presence does not impact clin-
ical outcomes in HLA-identical myeloablative
allogeneic transplant for AML, ALL, MDS, or CML.ACKNOWLEDGMENTS
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